[Federal Register Volume 59, Number 131 (Monday, July 11, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-16619]


[[Page Unknown]]

[Federal Register: July 11, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces a forthcoming meeting of a public 
advisory committee of the Food and Drug Administration (FDA). This 
notice also summarizes the procedures for the meeting and methods by 
which interested persons may participate in open public hearings before 
FDA's advisory committees.

MEETING: The following advisory committee meeting is announced:
Joint Subcommittee Meeting of the Nonprescription Drugs Advisory 
Committee and Arthritis Advisory Committee on Over-the-Counter Internal 
Analgesic, Antipyretic, and Antirheumatic Drug Products
    Date, time, and place. September 8 and 9, 1994, 8:30 a.m., Parklawn 
Bldg., conference rms. D and E, 5600 Fishers Lane, Rockville, MD.
     Type of meeting and contact person. Open committee discussion, 
September 8, 1994, 8:30 a.m. to 4 p.m.; open public hearing, 4 p.m. to 
5 p.m., unless public participation does not last that long; open 
committee discussion, September 9, 1994, 8:30 a.m. to 4 p.m., open 
public hearing, 4 p.m. to 5 p.m., unless public participation does not 
last that long; Lee L. Zwanziger, Center for Drug Evaluation and 
Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-443-4695.
    General function of the committees. The Nonprescription Drugs 
Advisory Committee reviews and evaluates available data concerning the 
safety and effectiveness of over-the-counter (nonprescription) human 
drug products for use in the treatment of a broad spectrum of human 
symptoms and diseases. The Arthritis Advisory Committee reviews and 
evaluates data on the safety and effectiveness of marketed and 
investigational human drugs for use in arthritic conditions.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the joint subcommittee. Those desiring to make formal presentations 
should notify the contact person before August 15, 1994, and submit a 
brief statement of the general nature of the information or arguments 
they wish to present, the names and addresses of proposed participants, 
and an indication of the approximate time requested to make their 
comments. In a subsequent issue of the Federal Register, FDA will 
publish a notice announcing the availability of background information.
    Open committee discussion. On September 8 and 9, 1994, the joint 
subcommittee will discuss effectiveness data requirements and proposed 
labeling indications for OTC analgesic drug products. The joint 
subcommittee will address topics such as: (1) Data requirements to 
support specific types of indications for OTC analgesic drug products; 
(2) recommendations for labeling indications for OTC analgesics; and 
(3) the current state of scientific knowledge in the areas of pain 
receptors, mechanism(s) of pain perception, and the basis for response 
to analgesic drug classes.
    FDA public advisory committee meetings may have as many as four 
separable portions: (1) An open public hearing, (2) an open committee 
discussion, (3) a closed presentation of data, and (4) a closed 
committee deliberation. Every advisory committee meeting shall have an 
open public hearing portion. Whether or not it also includes any of the 
other three portions will depend upon the specific meeting involved. 
There are no closed portions for the meetings announced in this notice. 
The dates and times reserved for the open portions of each committee 
meeting are listed above.
    The open public hearing portion of each meeting shall be at least 1 
hour long unless public participation does not last that long. It is 
emphasized, however, that the 1 hour time limit for an open public 
hearing represents a minimum rather than a maximum time for public 
participation, and an open public hearing may last for whatever longer 
period the committee chairperson determines will facilitate the 
committee's work.
    Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
part 10) concerning the policy and procedures for electronic media 
coverage of FDA's public administrative proceedings, including hearings 
before public advisory committees under 21 CFR part 14. Under 21 CFR 
10.205, representatives of the electronic media may be permitted, 
subject to certain limitations, to videotape, film, or otherwise record 
FDA's public administrative proceedings, including presentations by 
participants.
    Meetings of advisory committees shall be conducted, insofar as is 
practical, in accordance with the agenda published in this Federal 
Register notice. Changes in the agenda will be announced at the 
beginning of the open portion of a meeting.
    Any interested person who wishes to be assured of the right to make 
an oral presentation at the open public hearing portion of a meeting 
shall inform the contact person listed above, either orally or in 
writing, prior to the meeting. Any person attending the hearing who 
does not in advance of the meeting request an opportunity to speak will 
be allowed to make an oral presentation at the hearing's conclusion, if 
time permits, at the chairperson's discretion.
    The agenda, the questions to be addressed by the committee, and a 
current list of committee members will be available at the meeting 
location on the day of the meeting.
    Transcripts of the open portion of the meeting may be requested in 
writing from the Freedom of Information Office (HFI-35), Food and Drug 
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
approximately 15 working days after the meeting, at a cost of 10 cents 
per page. The transcript may be viewed at the Dockets Management Branch 
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
Rockville, MD 20857, approximately 15 working days after the meeting, 
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
minutes of the open portion of the meeting may be requested in writing 
from the Freedom of Information Office (address above) beginning 
approximately 90 days after the meeting.
    This notice is issued under section 10(a)(1) and (2) of the Federal 
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR 
part 14) on advisory committees.

    Dated: July 5, 1994.
 Linda A. Suydam,
 Interim Deputy Commissioner for Operations.
[FR Doc. 94-16619 Filed 7-8-94; 8:45 am]
BILLING CODE 4160-01-F